ProCE Banner Activity

CME

Advances in RCC, Prostate Cancer, and Urothelial Carcinoma at ASCO GU 2020

Conference Coverage
Clinical Thought
In this commentary, Robert Motzer, MD, and Daniel P. Petrylak, MD, share insights on the biggest developments and their clinical implications from ASCO GU 2020.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: March 31, 2020

Expiration: March 30, 2021

No longer available for credit.

Share

Faculty

Robert Motzer

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Daniel P. Petrylak

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Merck Sharp & Dohme Corp.

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with genitourinary cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with genitourinary cancers
  • Identify subpopulations of patients with cancer most likely to benefit from a specific treatment plan based on prognostic or predictive markers
  • Evaluate the unique mechanisms of action of promising investigational agents being studied for the treatment of genitourinary cancers
  • Discuss new data on novel agents and therapeutic approaches for patients with genitourinary cancers
  • Consider emerging clinical data on novel agents and therapeutic strategies that have the potential to improve outcomes for patients with genitourinary cancers

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Robert Motzer, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York

Robert Motzer, MD, has disclosed that he has received consulting fees from Eisai, Exelixis, Genentech/Roche, Merck, and Pfizer and funds for research support from Bristol-Myers Squibb, Eisai, Exelixis, Genentech/Roche, Lilly Oncology, and Pfizer.

Daniel P. Petrylak, MD

Professor of Medicine
Smilow Cancer Center
Yale University Medical Center
New Haven, Connecticut

Daniel P. Petrylak, MD, has disclosed that he has received consulting fees from Ada Cap (Advanced Accelerator Applications), Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Eli Lilly, Exelixis, Incyte, Janssen, Pfizer, Pharmacyclics, Roche Laboratories, Seattle Genetics, and Urogen; has received funds for research support from Ada Cap (Advanced Accelerator Applications), Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Clovis, Eli Lilly, Endocyte, Genentech, Innocrin, MedImmune, Merck, Novartis, Pfizer, Progenics, Roche Laboratories, Sanofi Aventis, Seattle Genetics; and has ownership interests in Bellicum and Tyme.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 31, 2020, through March 30, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with genitourinary cancers.